InVirtuoLabs is a Lugano-based biotech startup that integrates generative AI with advanced molecular simulations to accelerate drug discovery. Its core product is the proprietary Next Generation Virtual Lab platform, which combines multimodal learning, active learning, generative chemistry, and physics-based physics simulations to generate and test billions of new molecules. The company states this approach can double success rates and reduce both the cost and time of drug development compared with current methods. InVirtuoLabs developed a protocol targeting nuclear receptors and is applying it to a receptor implicated in high-incidence metabolic diseases. Founded in 2024 by Gianvito Grasso, Stefano Muscat, and Sertac Yeltekin, the team includes researchers and industry veterans with experience at Pfizer, Novo Nordisk, Baxter, and Helsinn. After closing a €2.85 million first funding round, the startup plans rapid expansion over the next 18 months to strengthen the team, initiate strategic collaborations, and expand platform capabilities.

Total raised

$3M

Funding rounds

1

Latest round

Equity

Latest activity

Feb 2025